Yes, the lowest ever enterprise valuation. The ridiculous thing is the unbelievable gap between the actual valuation versus the value proposition. It is perhaps the only biotech on the ASX with two late stage clinical drugs with proven efficacy so how Diamond leveraged this to a point where the enterprise value has sunk to zero is mind numbing.
His standard excuse is that the entire sector is like this and ANP is being treated like the sector. His passive acceptance an inability to leverage ANP's advantage over other biotechs is why he has failed.
At the very least, given what he earns he should be using this buying window to show the market that the company is ridiculously undervalued. Of course he is not obligated but what would you do? I would be buying as much as I can if I felt the company was grossly undervalued. I will add that having lost most of my investment in ANP over the many years I am not in his unique position of being the only winner associated with ANP.
